|Day Low/High||1.61 / 1.75|
|52 Wk Low/High||1.53 / 7.95|
Final Results of 24-Week Open-Label Phase 2 Trial Will be Presented by Professor Zohar Argov, MD, Senior Medical Advisor to BioBlast Pharma
BioBlast paints a very optimistic picture of Cabaletta's potential as an effective treatment for OPMD, but the data announced Tuesday are scant, cherry-picked and hardly conclusive.
Conference Call and Webcast, 8:30 a.m. Eastern Time
Conference Call and Webcast on Tuesday, October 27th at 8:30 a.m. Eastern Time
Appoints Former NPS and ViroPharma Executive, Paul Firuta as Chief Commercial Officer
The stock markets fluctuated and ended the trading session lower except the Dow Jones Industrial Average (DJIA), up 0.32%. Sign up for our free newsletter Companies in the semiconductor industry expe...
New Pivotal Study Reflects Positive Signals Reported From the Current HOPEMD Study, Which Will Be Closed Out at 25 Patients